📊 MED Key Takeaways
Is MED a Good Investment? Thesis Analysis
Medifast is experiencing severe operational distress with a 36% revenue collapse and a swing to significant net losses, indicating fundamental business deterioration rather than temporary headwinds. Despite strong balance sheet liquidity and zero debt, the company's negative operating margins, deteriorating profitability, and minimal free cash flow generation raise serious concerns about sustainability and the ability to recover without strategic restructuring.
Why Buy MED? Key Strengths
- Strong balance sheet with $89.3M cash and zero long-term debt
- Excellent liquidity position with 4.69x current ratio providing financial cushion
- High gross margins at 71.3% indicate the underlying product economics remain sound
MED Investment Risks to Consider
- Catastrophic revenue decline of 36% YoY signals loss of market demand or competitive positioning
- Operating losses of $14.2M and net losses of $18.7M indicate core business is unprofitable
- Free cash flow generation collapsed to just $1.2M (0.3% margin), leaving minimal runway for continued losses
- Negative ROE (-9.4%) and ROA (-7.5%) show value destruction for shareholders
- Operating cash flow of $6.9M provides insufficient buffer against mounting losses
Key Metrics to Watch
- Revenue stabilization and growth trajectory - critical to confirm bottom is in
- Path to operating profitability - must return to positive operating margins
- Free cash flow sustainability - need positive FCF generation exceeding losses
- Gross margin maintenance - monitor for further erosion below 71.3%
- Cash burn rate relative to cash reserves - current trajectory unsustainable long-term
MED Financial Metrics
💡 AI Analyst Insight
The relatively thin 0.3% FCF margin may limit capital allocation flexibility. Strong liquidity with a 4.69x current ratio provides a solid financial cushion.
MED Profitability Ratios
MED vs Consumer Sector
How MEDIFAST INC compares to Consumer sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MED Overvalued or Undervalued?
Based on fundamental analysis, MEDIFAST INC has mixed fundamental signals relative to the Consumer sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MED Balance Sheet & Liquidity
MED 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: MEDIFAST INC's revenue has declined by 33% over the 5-year period, indicating business contraction. The most recent EPS of $9.10 reflects profitable operations.
MED Growth Metrics (YoY)
MED Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $89.4M | -$553.0K | $-0.05 |
| Q2 2025 | $105.6M | $163.0K | $0.01 |
| Q1 2025 | $115.7M | -$772.0K | $-0.07 |
| Q3 2024 | $140.2M | $1.1M | $0.10 |
| Q2 2024 | $168.6M | $163.0K | $0.01 |
| Q1 2024 | $174.7M | $8.3M | $0.76 |
| Q3 2023 | $235.9M | $23.1M | $2.12 |
| Q2 2023 | $296.2M | $30.3M | $2.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MED Capital Allocation
MED SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for MEDIFAST INC (CIK: 0000910329)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MED
What is the AI rating for MED?
MEDIFAST INC (MED) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MED's key strengths?
Claude: Strong balance sheet with $89.3M cash and zero long-term debt. Excellent liquidity position with 4.69x current ratio providing financial cushion.
What are the risks of investing in MED?
Claude: Catastrophic revenue decline of 36% YoY signals loss of market demand or competitive positioning. Operating losses of $14.2M and net losses of $18.7M indicate core business is unprofitable.
What is MED's revenue and growth?
MEDIFAST INC reported revenue of $385.8M.
Does MED pay dividends?
MEDIFAST INC pays dividends, with $0.2M distributed to shareholders in the trailing twelve months.
Where can I find MED SEC filings?
Official SEC filings for MEDIFAST INC (CIK: 0000910329) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MED's EPS?
MEDIFAST INC has a diluted EPS of $-1.70.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MED a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MEDIFAST INC has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MED stock overvalued or undervalued?
Valuation metrics for MED: ROE of -9.4% (sector avg: 18%), net margin of -4.8% (sector avg: 8%). Compare these metrics with sector averages to assess valuation.
Should I buy MED stock in 2026?
Our dual AI analysis gives MEDIFAST INC a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MED's free cash flow?
MEDIFAST INC's operating cash flow is $6.9M, with capital expenditures of $5.6M. FCF margin is 0.3%.
How does MED compare to other Consumer stocks?
Vs Consumer sector averages: Net margin -4.8% (avg: 8%), ROE -9.4% (avg: 18%), current ratio 4.69 (avg: 1.5).